Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy

被引：0
作者：
Nermine H. Zakaria
Doaa Hashad
Marwa H. Saied
Neamat Hegazy
Alyaa Elkayal
Eman Tayae
机构：
[1] University of Alexandria,Department of Clinical and Chemical Pathology, Faculty of Medicine
[2] University of Alexandria,Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine
来源：
Human Genomics | / 17卷
关键词：
HER2-positive breast cancer; Genetic variants; NGS; Trastuzumab; Drug resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting
    Sheikh, Fareeha
    Nazir, Adil
    Yasmeen, Samia
    Badar, Farhana
    Ahmad, Usman
    Siddiqui, Neelam
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2019, 29 (02): : 159 - 163
  • [42] Beyond trastuzumab: New treatment options for HER2-positive breast cancer
    Saini, Kamal S.
    Azim, Hatem A., Jr.
    Metzger-Filho, Otto
    Loi, Sherene
    Sotiriou, Christos
    de Azambuja, Evandro
    Piccart, Martine
    BREAST, 2011, 20 : S20 - S27
  • [43] Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
    Du, Jiaqun
    Liu, Xiaobang
    Sun, Junpeng
    Wu, Qian
    Hu, Yu
    Shi, Huan
    Zheng, Li
    Liu, Ying
    Wu, Chao
    Gao, Yu
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [44] Markers of inflammation as predictors of efficacy of trastuzumab therapy in HER2-positive metastatic breast cancer patients
    Vynnychenko, O.
    Moskalenko, Y.
    Moskalenko, R.
    REGULATORY MECHANISMS IN BIOSYSTEMS, 2025, 16 (01)
  • [45] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    BMC CANCER, 2018, 18
  • [46] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Volkmar Müller
    Michael Clemens
    Jacek Jassem
    Nedal Al-Sakaff
    Petra Auclair
    Eveline Nüesch
    Debbie Holloway
    Mona Shing
    Yung-Jue Bang
    BMC Cancer, 18
  • [47] The impact of trastuzumab therapy and cardiovascular risk factors on cardiac function in HER2-positive breast cancer patients
    Krstic, I
    Deljanin-Ilic, M.
    Pejcic, I
    Vrbic, S.
    Marinkovic, D.
    Stojanovic, M.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2021, 35 (06) : 1803 - 1815
  • [48] Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review
    Ventura, Ignacio
    Salcedo, Nerea Pinilla
    Perez-Bermejo, Marcelino
    Perez-Murillo, Javier
    Tejeda-Adell, Manuel
    Tomas-Aguirre, Francisco
    Legidos-Garcia, Maria Ester
    Murillo-Llorente, Maria Teresa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [49] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    M Cizkova
    M-E Dujaric
    J Lehmann-Che
    V Scott
    O Tembo
    B Asselain
    J-Y Pierga
    M Marty
    P de Cremoux
    F Spyratos
    I Bieche
    British Journal of Cancer, 2013, 108 : 1807 - 1809
  • [50] Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
    Gradishar, W. J.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2492 - 2500
12345